Can we predict chemo nerve damage in kids? new study aims to find out

NCT ID NCT07326930

Recruiting now Knowledge-focused Sponsor: The Hong Kong Polytechnic University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study follows 173 children aged 8 to 17 with acute lymphoblastic leukemia who are receiving a chemotherapy drug called vincristine. Researchers will measure nerve damage at several points during treatment and look for factors like symptoms, nutrition, sleep, and activity that might predict who will have more severe problems. The goal is to understand patterns of nerve damage so doctors can better support children during chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which children are at higher risk for nerve damage from chemotherapy, allowing for earlier monitoring or adjustments.
What could go wrong: This is an observational study, not a treatment trial. It will not directly improve outcomes, and the findings may not apply to all children or chemotherapy regimens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Contacts and locations

Locations

Shanghai Children's Medical Center
RECRUITING

Shanghai, China
Shenzhen Children's Hospital
RECRUITING

Shenzhen, China
The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital,
RECRUITING

Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.